This updated assessment tool, which outlines the indicators for human health and the joint parts of the country visits, should be used in conjunction with respective EC assessment tools for the veterinary and environmental sectors. The updated assessment tool was drafted after an expert consultation meeting in Stockholm on 5–6 February 2020 and finalised after review by the participating experts.
This toolkit, jointly created by the World Health Organization (WHO) Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC), provides event organisers with customisable tools on monkeypox for mass gatherings, both for consideration and use.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
This update of ECDC’s rapid risk assessment on the Zika epidemic considers the recent epidemiological and scientific information in light of the risk to Europe and European citizens.
This protocol prescribes the methodology, and provides the data collection tools required to achieve the objectives of European surveillance of Clostridium difficile infections (CDIs).
The aim of this rapid literature review is to bring together knowledge and research related to vaccine hesitancy in EU /EEA countries into a format that is easy to understand and follow.
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
This ECDC infographic explains how antivirals treat and protect against influenza. The recommendations to treat patients with severe influenza are based on the evidence from randomised controlled trials, observational studies, extrapolation from studies, and a generally benign safety profile of these medicines.
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.